Medscape: Defending MDMA as Treatment for PTSD

Summary: Medscape publishes an editorial with MAPS’ response to a recent Medscape video presentation by Dr. Jeffrey Lieberman in which the author expresses concern about psychedelic therapy research, including MDMA research. In the editorial, MAPS researchers and staff highlight recent research, explaining how Dr. Lieberman’s critiques do not accurately reflect the results of Phase 1 and Phase 2 trials of MDMA-assisted psychotherapy for PTSD, nor do they correctly describe its proposed mechanism of action. “We firmly agree that, like any other treatment, MDMA should be investigated with rigor and care, and its acceptance based on results from randomized, controlled clinical trials,” the researchers write. “However, his statements do not accurately reflect findings from phase 1 and 2 studies of MDMA in clinical settings, nor its proposed mechanism of action as an adjunct to therapy.”

Read the Publication